What is HC Wainwright’s Forecast for SMMT FY2026 Earnings?

Summit Therapeutics PLC (NASDAQ:SMMT) – Stock analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of Summit Therapeutics in a research note issued to investors on Friday, July 24th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.06) for the year, down from their previous estimate of ($1.05). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Summit Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Summit Therapeutics’ Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($1.05) EPS.

Summit Therapeutics (NASDAQ:SMMT) last announced its quarterly earnings data on Thursday, July 23rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Several other equities analysts have also recently issued reports on the stock. Jefferies Financial Group set a $15.00 price objective on shares of Summit Therapeutics in a research note on Friday. Citigroup assumed coverage on shares of Summit Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating for the company. Guggenheim decreased their price target on shares of Summit Therapeutics from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday. Piper Sandler dropped their price target on Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a report on Friday, May 1st. Finally, Stifel Nicolaus reduced their price objective on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $26.15.

Summit Therapeutics Trading Down 4.2%

Shares of Summit Therapeutics stock opened at $12.55 on Wednesday. The company’s 50-day moving average price is $14.90 and its two-hundred day moving average price is $16.59. Summit Therapeutics has a 52 week low of $12.25 and a 52 week high of $30.98. The stock has a market cap of $10.01 billion, a PE ratio of -11.21 and a beta of -1.26.

Insider Transactions at Summit Therapeutics

In other Summit Therapeutics news, CEO Robert W. Duggan bought 3,810,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the transaction, the chief executive officer directly owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. This represents a 0.67% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Manmeet Singh Soni acquired 50,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were acquired at an average price of $14.45 per share, with a total value of $722,500.00. Following the completion of the transaction, the chief financial officer directly owned 3,123,603 shares in the company, valued at approximately $45,136,063.35. This trade represents a 1.63% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 7,870,000 shares of company stock valued at $103,616,900 over the last ninety days. Corporate insiders own 83.50% of the company’s stock.

Institutional Trading of Summit Therapeutics

Several institutional investors have recently made changes to their positions in SMMT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Summit Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock valued at $1,273,000 after purchasing an additional 694 shares in the last quarter. Fifth Third Bancorp lifted its position in Summit Therapeutics by 24.4% in the 1st quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock worth $71,000 after buying an additional 732 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Summit Therapeutics by 3.3% during the 3rd quarter. Sei Investments Co. now owns 27,163 shares of the company’s stock valued at $561,000 after buying an additional 860 shares during the period. Levin Capital Strategies L.P. grew its holdings in shares of Summit Therapeutics by 2.7% during the 4th quarter. Levin Capital Strategies L.P. now owns 37,676 shares of the company’s stock valued at $659,000 after acquiring an additional 1,000 shares in the last quarter. Finally, State of Wisconsin Investment Board increased its stake in shares of Summit Therapeutics by 1.1% in the fourth quarter. State of Wisconsin Investment Board now owns 92,882 shares of the company’s stock worth $1,625,000 after acquiring an additional 1,047 shares during the last quarter. 4.61% of the stock is currently owned by institutional investors and hedge funds.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.